Clinical Publication
RSSArticles
-
Can Cognitive Behavioral Therapy Help with Insomnia?
In this randomized clinical trial, telephone-administered cognitive behavioral therapy for insomnia significantly outperformed education alone in alleviating insomnia and reducing daytime fatigue in older adults with osteoarthritis pain.
-
Exploring the Relationship Between Alcohol and Cardiovascular Events
Researchers reported consuming two to 14 alcoholic drinks per week was associated with fewer major adverse cardiovascular events, which the authors noted could be explained in part by less stress-related neural activity demonstrated on PET and CT scans.
-
Running to Keep Ahead of Coronary Artery Disease
In this cross-sectional review of the Master Athlete Heart study, the authors found lifelong endurance sport participation was not associated with a more favorable coronary plaque composition vs. a healthy lifestyle. Lifelong endurance athletes exhibited more coronary plaques.
-
More Reports of Severe Group A Streptococcal Infection
Around the world, rates of severe illness caused by group A Streptococcus are rising. Possible explanations for the increase include immunity-altering, post-pandemic changes in exposure to respiratory pathogens and the emergence of new pathogenic M strains of Streptococcus.
-
Steroids and Pneumonia — So Meta?
In a multicenter, randomized, placebo-controlled trial, hydrocortisone lowered mortality rates among patients with severe community-acquired pneumonia.
-
COVID-19 Vaccine, 2023-2024 Formula (Comirnaty, Spikevax)
The newest vaccines target XBB.1.5, which is no longer the dominant circulating variant, but they offer protection against XBB.1.16 and more distant variants (e.g., EG.5.1, FL.1.1.1, and BA.2.86).
-
Is the Irregularity a Problem?
Interpreting ECGs without the benefit of any history always is challenging. Such is the case with the figure in this article, which manifests significant irregularity.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
More than 500 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment vs. placebo.
-
Oral Penicillin Challenge vs. Skin Testing: Diagnosing Low-Risk Patients with Reported Penicillin Allergy
In a comparison of direct oral penicillin challenge in low-risk patients to skin testing followed by oral challenge, researchers reported no significant differences. Direct oral penicillin challenge appears to be a safe and effective way to delabel a penicillin allergy.
-
Researchers Report on the Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator
An FDA-mandated post-approval study of the subcutaneous cardioverter-defibrillator system in a real-world population revealed excellent safety and efficacy over five years.